Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of methylmalonic acid as biomarker in predicting heart failure after myocardial infarction

A methylmalonic acid and biomarker technology, applied in the field of medicine, can solve problems such as underestimation, affecting the prognosis of patients with myocardial infarction, and affecting mitophagy

Pending Publication Date: 2022-07-08
HARBIN MEDICAL UNIVERSITY
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, MMA may be an underestimated biomarker of cardiovascular disease prognosis
At the same time, through in-depth exploration of the mechanism of MMA, the applicant found that MMA can affect mitophagy, thereby affecting the prognosis of patients with myocardial infarction

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of methylmalonic acid as biomarker in predicting heart failure after myocardial infarction
  • Application of methylmalonic acid as biomarker in predicting heart failure after myocardial infarction
  • Application of methylmalonic acid as biomarker in predicting heart failure after myocardial infarction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Example 1 Methylmalonic acid as a biomarker for predicting the occurrence of heart failure after myocardial infarction

[0032] method:

[0033] 1. Statistical baseline data

[0034] More than 500 patients with clinical acute myocardial infarction (AMI) were included, of which more than 300 patients underwent blood collection and cryopreservation in the sample bank. According to Propensity Score Matching (PSM), 49 pairs of patients with or without heart failure after myocardial infarction were matched. patients, and their baseline data were collected.

[0035] 2. Pre-processing of plasma samples

[0036] 1) Collect peripheral venous blood in an emergency, separate monocytes, platelets, and plasma according to the standard procedure of the biological sample bank, and then pack and freeze it in the biological sample bank - -80 ℃ refrigerator.

[0037] 2) After confirming the inclusion of the research subjects, place the samples at 4°C to thaw slowly after being release...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of methylmalonic acid as a biomarker in predicting heart failure after myocardial infarction. The invention also discloses application of the reagent or the instrument for detecting methylmalonic acid in preparation of the reagent or the device for predicting heart failure after myocardial infarction. Wherein preferably, the device is a rapid separation liquid chromatogram-quadrupole rod-flight time mass spectrum combined instrument. According to the invention, MMA is found as a biological prediction target for predicting heart failure after myocardial infarction for the first time, and the blank in the field that a current conventional biomarker cannot accurately predict heart failure after myocardial infarction is filled up. According to the application disclosed by the invention, the treatment strategy of patients with myocardial infarction is greatly improved, a new technical means is provided for the occurrence mechanism and early diagnosis of heart failure after myocardial infarction, and a potential theoretical basis is also provided for effective treatment of heart failure after myocardial infarction.

Description

technical field [0001] The invention relates to a biomarker for predicting the occurrence of heart failure after myocardial infarction and its application, in particular to the application of methylmalonic acid as a biomarker in predicting the occurrence of heart failure after myocardial infarction. The invention belongs to the technical field of medicine. Background technique [0002] Myocardial infarction (MI) is a myocardial ischemia necrosis caused by rupture of coronary atherosclerotic plaque that blocks the coronary lumen. Heart failure (HF) is a syndrome of cardiac circulatory disorder caused by the failure of the systolic and / or diastolic function of the heart to fully discharge the venous blood back to the heart. Studies have found that myocardial infarction is one of the most common and important causes of heart failure. In recent years, although guidance documents for myocardial infarction and heart failure have been released respectively, the problems of high i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N30/06G01N30/08G01N30/88
CPCG01N30/06G01N30/08G01N30/88
Inventor 房绍红王善杰郭俊辰王也于波
Owner HARBIN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com